Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Publication outcome of abstracts submitted to the American Academy of Ophthalmology meeting.

Mimouni M, Krauthammer M, Abualhasan H, Badarni H, Imtanis K, Allon G, Berkovitz L, Blumenthal EZ, Mimouni FB, Amarilyo G.

J Med Libr Assoc. 2018 Jan;106(1):57-64. doi: 10.5195/jmla.2018.314. Epub 2018 Jan 2.

2.

Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding.

Al-Badriyeh D, Alameri M, Al-Okka R.

BMJ Open. 2017 Jan 27;7(1):e012648. doi: 10.1136/bmjopen-2016-012648. Review.

3.

Paroxetine versus other anti-depressive agents for depression.

Cipriani A, Furukawa TA, Veronese A, Watanabe N, Churchill R, McGuire H, Barbui C.

Cochrane Database Syst Rev. 2007;(2). pii: CD006531.

4.

Venlafaxine versus other anti-depressive agents for depression.

Cipriani A, Signoretti A, Furukawa TA, Churchill R, Tomelleri S, Omori IM, McGuire H, Barbui C.

Cochrane Database Syst Rev. 2007;(2). pii: CD006530.

5.
6.

A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design.

Goswami ND, Tsalik EL, Naggie S, Miller WC, Horton JR, Pfeiffer CD, Hicks CB.

Trials. 2014 Jan 22;15:31. doi: 10.1186/1745-6215-15-31.

7.

Industry influence in evidence production.

Dunn AG, Bourgeois FT, Coiera E.

J Epidemiol Community Health. 2013 Jul;67(7):537-8. doi: 10.1136/jech-2013-202344. Epub 2013 Jan 30. No abstract available.

8.

Duloxetine versus other anti-depressive agents for depression.

Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533. doi: 10.1002/14651858.CD006533.pub2. Review.

9.

Citalopram versus other anti-depressive agents for depression.

Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD006534. doi: 10.1002/14651858.CD006534.pub2. Review.

10.

Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis.

Khan NA, Lombeida JI, Singh M, Spencer HJ, Torralba KD.

Arthritis Rheum. 2012 Jul;64(7):2059-67. doi: 10.1002/art.34393.

11.

Mirtazapine versus other antidepressive agents for depression.

Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2. Review.

12.

A systematic review of research on the meaning, ethics and practices of authorship across scholarly disciplines.

Marušić A, Bošnjak L, Jerončić A.

PLoS One. 2011;6(9):e23477. doi: 10.1371/journal.pone.0023477. Epub 2011 Sep 8. Review.

13.

The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.

Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K.

Dtsch Arztebl Int. 2010 Apr;107(16):279-85. doi: 10.3238/arztebl.2010.0279. Epub 2010 Apr 23. Review.

14.

Sertraline versus other antidepressive agents for depression.

Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006117. doi: 10.1002/14651858.CD006117.pub4. Review.

15.

Fluvoxamine versus other anti-depressive agents for depression.

Omori IM, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006114. doi: 10.1002/14651858.CD006114.pub2. Review.

16.

Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.

Rose SL, Krzyzanowska MK, Joffe S.

J Clin Oncol. 2010 Mar 10;28(8):1316-21. doi: 10.1200/JCO.2008.21.6606. Epub 2010 Jan 11.

17.

Milnacipran versus other antidepressive agents for depression.

Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006529. doi: 10.1002/14651858.CD006529.pub2. Review.

18.

Factors associated with results and conclusions of trials of thiazolidinediones.

Rattinger G, Bero L.

PLoS One. 2009 Jun 8;4(6):e5826. doi: 10.1371/journal.pone.0005826.

19.

Escitalopram versus other antidepressive agents for depression.

Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006532. doi: 10.1002/14651858.CD006532.pub2. Review.

20.

Negative pressure wound therapy: potential publication bias caused by lack of access to unpublished study results data.

Peinemann F, McGauran N, Sauerland S, Lange S.

BMC Med Res Methodol. 2008 Feb 11;8:4. doi: 10.1186/1471-2288-8-4. Review.

Supplemental Content

Support Center